SBIR Phase II: A Novel Device for Convenient Therapeutic Drug Monitoring of Tacrolimus
SBIR Phase II: A Novel Device for Convenient Therapeutic Drug Monitoring of Tacrolimus
批准号:
1330934
负责人:
Tian Lan
金额:
$75.0万
依托单位:
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-10-01 至 2016-03-31
中文摘要
这个小型企业创新研究(SBIR)第二阶段项目旨在开发和验证他克莫司的护理点监测,他克莫司是一种广泛用于器官移植患者的免疫抑制药物。正在开发的产品将现有的、开发完善的低成本葡萄糖测定仪技术与黄金标准免疫分析平台相结合,从而产生一种可能改善移植患者治疗结果的产品。目前,他克莫司血药浓度监测多采用实验室方法,周期长,监测频度较高。然而,他克莫司是一种毒性水平仅比其治疗水平高几倍的药物,目前不频繁的监测方法不太有效,无法确保患者的最有效药物水平。第二阶段的项目将首先优化第一阶段开发的基于血糖计的他克莫司测定仪,然后开发和验证装有该测定仪的一次性设备和具有更高灵敏度的血糖监测仪。我们预计,由一次性和阅读器组成的系统将在第二阶段项目结束时开发和验证,为临床验证做好技术准备。该项目更广泛的影响/商业潜力在于未来技术的发展,这将扩大他克莫司以外的潜在测试目标。目前市场上许多药物的治疗范围很窄,以及许多有效的药物由于缺乏密切的监测方法来减少其毒性作用而无法上市。我们正在开发的创新治疗药物监测设备将使其中许多药物变得更容易获得。对于我们目前的目标市场,全球数十万移植患者在余生中使用他克莫司,我们产品的商业潜力是巨大的。社会影响是相当大的,仅就肾移植而言,29%的同种异体移植将在未来五年内失败,原因是免疫抑制药物管理不当,失败后的治疗和透析花费了数亿美元。为患者提供管理药物的便捷工具,可以显著减少肾功能衰竭的数量,为患者带来更好的生活,为社会节省巨额资金。
英文摘要
This Small Business Innovation Research (SBIR) Phase II project is aiming to develop and validate a point-of-care monitoring for tacrolimus, an immunosuppressive medication widely used by organ transplant patients. The product being developed combines the existing, well-developed and low cost glucose meter technology with the gold standard immunoassay platform, leading to a product that can potentially improve the treatment outcome of transplant patients. Currently, monitoring of tacrolimus level is achieved by using laboratory assays, which has a long turn-around time and frequent monitoring is more difficult. However, tacrolimus is a drug whose toxic level is only couple times higher than its therapeutic level, and current infrequent monitoring approach is less effective to ensure the most effective drug levels in patients. The Phase II project will be achieved by first optimizing the glucose meter based tacrolimus assay developed in Phase I, following by the development and validation a disposable device which will house the assay and a glucose monitor which has an improved sensitivity. We anticipated the system composed of a disposable and a reader will be developed and validated at the end of the Phase II project, preparing the technology for clinical validation.The broader impact/commercial potential of this project lies in the future development of the technology that will expand the potential test targets beyond tacrolimus. Numerous drugs currently on the market have a narrow therapeutic range, as well as many effective drugs that cannot be marketed due to lack of close monitoring methods to reduce their toxic effects. The innovative therapeutic drug monitoring device we are developing will allow many of these drugs become more available. For our current target market, with hundreds of thousands of transplant patients using tacrolimus worldwide for the remainder of their lives, the commercial potential for our product is immense. The social impact is considerable, and for just kidney transplants, 29% of the allografts will fail in the next five years due to improperly managed immunosuppressant medications costing hundreds of millions of dollars for post failure treatment and dialysis. Providing patients with a convenient tool to manage their medication can significantly reduce the number of failed kidneys, leading to better life to the patient and huge savings for the society.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
I-Corp: A Data-Driven Cloud Optimization Tool
-
批准号:2036231
-
项目类别:Standard Grant
-
资助金额:$5.0万
-
财政年份:2020
-
负责人:Tian Lan
-
依托单位:
NeTS: Small: Collaborative Research: Rethinking Erasure Codes for Cloud Storage: A Quantitative Framework for Latency, Reliability, and Cost Optimization
-
批准号:1618628
-
项目类别:Continuing Grant
-
资助金额:$25.0万
-
财政年份:2016
-
负责人:Tian Lan
-
依托单位:
CSR: Small: Reliability as a Service (RaaS) in Cloud Computing
-
批准号:1320226
-
项目类别:Standard Grant
-
资助金额:$40.8万
-
财政年份:2013
-
负责人:Tian Lan
-
依托单位:
SBIR Phase I: Novel Biosensor for Monitoring of Theophylline using Personal Glucose Meter
-
批准号:1215421
-
项目类别:Standard Grant
-
资助金额:$15.0万
-
财政年份:2012
-
负责人:Tian Lan
-
依托单位:
CSR: Small: Collaborative Research: Per-Process Energy Accounting in Mobile Systems
-
批准号:1218200
-
项目类别:Standard Grant
-
资助金额:$22.0万
-
财政年份:2012
-
负责人:Tian Lan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark
Supercooled Phase Transition
-
批准号:24ZR1429700
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:YUICHIRO NAKAI
-
依托单位:
ATLAS实验探测器Phase 2升级
-
批准号:11961141014
-
项目类别:国际(地区)合作与交流项目
-
资助金额:3350万元
-
批准年份:2019
-
负责人:刘衍文
-
依托单位:
地幔含水相Phase E的温度压力稳定区域与晶体结构研究
-
批准号:41802035
-
项目类别:青年科学基金项目
-
资助金额:12.0万元
-
批准年份:2018
-
负责人:张里
-
依托单位:
基于数字增强干涉的Phase-OTDR高灵敏度定量测量技术研究
-
批准号:61675216
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2016
-
负责人:叶青
-
依托单位:
基于Phase-type分布的多状态系统可靠性模型研究
-
批准号:71501183
-
项目类别:青年科学基金项目
-
资助金额:17.4万元
-
批准年份:2015
-
负责人:陈童
-
依托单位:
纳米(I-Phase+α-Mg)准共晶的临界半固态形成条件及生长机制
-
批准号:51201142
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2012
-
负责人:张英波
-
依托单位:
连续Phase-Type分布数据拟合方法及其应用研究
-
批准号:11101428
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:黄卓
-
依托单位:
D-Phase准晶体的电子行为各向异性的研究
-
批准号:19374069
-
项目类别:面上项目
-
资助金额:6.4万元
-
批准年份:1993
-
负责人:张殿琳
-
依托单位: